- Home
- NLOP vs ATXS Comparison
NLOP vs ATXS Comparison
Compare NLOP & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLOP
- ATXS
- Stock Information
- Founded
- NLOP 2022
- ATXS 2008
- Country
- NLOP United States
- ATXS United States
- Employees
- NLOP N/A
- ATXS N/A
- Industry
- NLOP
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- NLOP
- ATXS Health Care
- Exchange
- NLOP Nasdaq
- ATXS Nasdaq
- Market Cap
- NLOP 467.2M
- ATXS 401.2M
- IPO Year
- NLOP N/A
- ATXS 2015
- Fundamental
- Price
- NLOP $30.08
- ATXS $6.64
- Analyst Decision
- NLOP Strong Buy
- ATXS Strong Buy
- Analyst Count
- NLOP 1
- ATXS 6
- Target Price
- NLOP $46.00
- ATXS $26.67
- AVG Volume (30 Days)
- NLOP 109.1K
- ATXS 248.3K
- Earning Date
- NLOP 01-01-0001
- ATXS 03-11-2025
- Dividend Yield
- NLOP 1.11%
- ATXS N/A
- EPS Growth
- NLOP N/A
- ATXS N/A
- EPS
- NLOP N/A
- ATXS N/A
- Revenue
- NLOP $142,247,000.00
- ATXS N/A
- Revenue This Year
- NLOP N/A
- ATXS N/A
- Revenue Next Year
- NLOP N/A
- ATXS N/A
- P/E Ratio
- NLOP N/A
- ATXS N/A
- Revenue Growth
- NLOP N/A
- ATXS N/A
- 52 Week Low
- NLOP $22.16
- ATXS $5.73
- 52 Week High
- NLOP $34.38
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- NLOP 35.62
- ATXS 47.97
- Support Level
- NLOP $31.49
- ATXS $5.73
- Resistance Level
- NLOP $30.88
- ATXS $6.88
- Average True Range (ATR)
- NLOP 0.70
- ATXS 0.46
- MACD
- NLOP -0.24
- ATXS 0.10
- Stochastic Oscillator
- NLOP 1.43
- ATXS 58.33
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.